In 2014, Cures Within Reach collaborated with the Alzheimer’s Drug Discovery Foundation and others to fund Dr. Krista Lanctôt at Sunnybrook Health Sciences Centre and this now-completed randomized, placebo-controlled clinical trial testing nabilone, a cannabinoid used to treat nausea and vomiting caused by cancer chemotherapy, to treat agitation in Alzheimer’s disease. She is now leading the larger, confirmatory Phase III trial.

Dr. Lanctôt is a distinguished figure in clinical pharmacology, with over 400 published manuscripts. She holds the Bernick Chair in Geriatric Psychopharmacology at Sunnybrook Health Sciences Centre and the University of Toronto. Her research is concentrated on neurocognitive disorders, with an emphasis on Alzheimer’s disease and vascular cognitive impairment. She serves as Sunnybrook’s Director of Neuropsychopharmacology Research Program and Research Director of Psychiatry, where her pioneering research is significantly contributing to the understanding and treating neurological conditions. In addition, she is a Professor of Psychiatry and of Pharmacology and Toxicology, and Vice Chair, Basic and Clinical Sciences in the Department of Psychiatry at the University of Toronto.

She was drawn to her focus in neuropsychiatric symptoms of dementia-related diseases (mood and behavior symptoms such as apathy and agitation), due to their significant impact yet lack of treatment options. Her goal: to find treatment options that reduce the impact of these neuropsychiatric symptoms.